Infinity Pharmaceuticals | INFI - Cash And Equivalent


Infinity Pharmaceuticals reported $17.75M in Cash and Equivalent for its fiscal quarter ending in June of 2023.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Incyte USD 4.02B 435.22M Mar/2026
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Plus Therapeutics USD 3.02M 1.23M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 442.21M 242.7M Mar/2026